Clinical Trial for Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome

X Fragile Syndrome Clinical Trial

— SXF2-8  

Official title:

Clinical Trials Phase III, Double Blind, Crossover to Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02942498
• Other study ID #: SXF2-8
• Status: Completed
• Phase: Phase 3
• Start date: July 2016
• Est. completion date: October 31, 2018

Study information

• Verified date: September 2016
• Source: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine vitamin C and vitamin E in combination are effective in the treatment of cognitive and behavior disorder in children with fragile X syndrome.

Description:

The combination of vitamin E and vitamin C supplementation has been associated with a lower prevalence (-78%) and incidence (-64%) of Alzheimer's disease in the elderly population. It has recently been shown that dietary vitamin E supplementation reduces the production of free radicals inhibiting NADPH oxidase activity in circulating neutrophils. Another work describes the inhibition of glutamate release by activated microglia in cell cultures incubated with vitamin E, effect that can prevent excitotoxicity. The investigators propose to evaluate the effectiveness of treatment in neurodevelopmental disorders affected by fragile X syndrome (FXS) with lipophilic compounds antioxidants such as tocopherol and hydrophilic compounds antioxidants such as ascorbic acid, which regulate oxidative stress and improve learning and behavioral mouse model and humans. Our group has positive results in the use of this combination of antioxidants as a treatment for fragile X syndrome in adolescents. This disease has developed previous clinical trials with EUDRACT codes: 2009-017837-23 and 2013-004276-35. The use of the combination of vitamin C and E in the treatment of cognitive and behavioral disorder in FXS, is patented PCT-050 187 with reference number 2011070875 This combination will be administered as a single oral dose with a total dose of 10mg / kg / day for each of the vitamins. This dose is maintained within the therapeutic range of both antioxidants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: October 31, 2018
• Est. primary completion date: September 25, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 8 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of Fragile X syndrome by genetic testing of molecular biology, full mutation result methylation.

2. Having an older age of 1 year and less than 9 years

3. Having signed the informed consent document before starting their participation in the trial.

Exclusion Criteria:

1. Any advanced, severe or unstable disease.

2. Individuals with other psychiatric diagnosis as the first diagnosis.

3. It have been suffered serious medical problems in the last 12 months.

4. Be taking more than 100 mg of vitamin E or C a day in the last month.

5. Having physical, mental or sensory impairments that prevent the assessment of effectiveness.

6. Hypersensitivity to any component of the preparation.

7. Liver failure or severe renal or previous history of kidney stones.

8. Any treatment regimen, including treatment with psychotropic drugs and / or anticonvulsant therapy that has not been stable for a period = 4 weeks before randomization.

9. Current treatment with more than two psychoactive medications, excluding medication used specifically for the control of seizures.

10. Hypoprothrombinemia secondary to vitamin K deficiency

11. Sensitivity to any of the compounds of formula treatment.

12. Patients diagnosed with congenital or idiopathic methemoglobinemia for diagnosis of glucose-6-phosphate dehydrogenase deficiency.

13. Use of oral anticoagulants, iron or vitamin A.

14. Forecast initiate or change pharmacological or no pharmacological interventions during the course of the study.

15. Patients weighing less than 4.2 kg

Related Conditions & MeSH terms

• Child Behavior Disorders
• Fragile X Syndrome
• Mental Disorders
• Syndrome
• X Fragile Syndrome

Intervention

Drug:
• Vitamin C 10mg/Kg Vitamin E 10 mg/Kg

• Placebo
Placebo

Locations

Country	Name	City	State
Spain	Hospital Regional de Málaga	Malaga	Málaga

Sponsors (2)

Lead Sponsor	Collaborator
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud	Delos Clinical

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Barger SW, Goodwin ME, Porter MM, Beggs ML. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem. 2007 Jun;101(5):1205-13. Epub 2007 Mar 30. — View Citation

Castilla P, Dávalos A, Teruel JL, Cerrato F, Fernández-Lucas M, Merino JL, Sánchez-Martín CC, Ortuño J, Lasunción MA. Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. Am J Clin Nutr. 2008 Apr;87(4):1053-61. — View Citation

Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004 Jan;61(1):82-8. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Autism Treatment Evaluation Checklist (ATEC).		32 weeks
Primary	Global Clinical Impression (GCI)		32 weeks
Primary	Peabody Picture Vocabulary Test (PiVT)		32 weeks
Primary	Battelle developmental inventory screening		32 weeks
Primary	Vineland Adaptive Behavior Scales		32 weeks
Primary	Adverse event reported		32 weeks
Primary	Quantitative Checklist for Autism in Toddlers (Q-Chat) test		32 weeks
Secondary	Golberg scale GHQ-28		32 weeks
Secondary	Quality life SF36 test		32 weeks
Secondary	Psychological General Well-Being Index		32 weeks
Secondary	Sleep Disturbance Scale for Children		32 weeks